FRE logo

Firebrick Pharma Limited Stock Price

ASX:FRE Community·AU$13.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

FRE Share Price Performance

AU$0.053
-0.03 (-39.08%)
AU$0.053
-0.03 (-39.08%)
Price AU$0.053

FRE Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with very low risk.

2 Risks
0 Rewards

Firebrick Pharma Limited Key Details

AU$410.7k

Revenue

AU$217.8k

Cost of Revenue

AU$192.9k

Gross Profit

AU$2.6m

Other Expenses

-AU$2.5m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.0097
46.96%
-596.85%
0%
View Full Analysis

About FRE

Founded
2012
Employees
n/a
CEO
Peter Molloy
WebsiteView website
firebrickpharma.com

Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Recent FRE News & Updates

Recent updates

No updates